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The focus of this thesis is on functional neuroimaging of affective processing in 
psychiatric disorders. In the first part of this thesis, I present a prospective and a 
longitudinal functional magnetic resonance (fMRI) study on affective processing to 
investigate whether brain abnormalities 1) could predict the long-term course of 
depression; 2) depend on the clinical depressive state and progress with enduring 
depressive course. In the second part of the thesis, I focus on symptom specific 
neural abnormalities in depression, namely suicidality, and on distinctive 
abnormalities in emotion regulation in psychiatric disorders characterized by 
affective dysregulation: schizophrenia and bipolar disorder. Because depression is 
associated with a high suicidal risk, I sought to unravel 3) whether neural correlates 
of affective and cognitive control could be a candidate marker of suicidality. Finally, I 
investigated 4) the temporal markers of brain activation during emotion regulation in 
schizophrenia and bipolar disorder. In this introduction, an overview of the clinical 
characteristics, prevalence, illness course and symptom specificity in depression will 
be presented first. Then, the neurobiological models of affective processing in 
psychiatric disorders will be briefly reviewed. Finally, I will introduce the aims and 
outline of this thesis. 
Major depressive disorder (MDD) 
Clinical characteristics and prevalence 
MDD is a psychiatric disorder characterized by enduring sadness, loss of interest or 
pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of 
tiredness, and poor concentration (See Box I for Diagnostic and Statistical Manual of 
Mental Disorders-version 5 [DSM-5] for MDD) (American Psychiatric Association 
2013). Currently, MDD is a leading cause of disability worldwide, with an estimate of 
more than 350 million people affected (Marcus et al, 2012). Recently, the World 
Mental Health survey by the World Health Organization reported that the lifetime 
prevalence of major depressive episode (MDE) across the world ranges from 6.5% 
(People’s Republic of China) and 6.6% (Japan) to 21.0% (France) and 19.2% (the USA) 
(Bromet et al, 2011; Kessler and Bromet 2013). Average twelve-month prevalence 
rates range from 5.5% to 5.9% (Bromet et al, 2011).  
Social-demographic factors such as sex, age, and marital status are associated 
with depression (Kessler and Bromet 2013). Women typically have a two-fold higher 
risk of MDD compared to men (Van de Velde et al, 2010). The typical age of onset of 
depression is in the early to mid twenties (Kessler and Bromet 2013) and prevalence 
decreases with age (Andrade et al, 2003). Being separated or divorced predicts 




Box I. Diagnostic Criteria for Major Depressive Disorder [DSM-5] 
A. Five (or more) of the following symptoms have been present during the same 2-
week period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure. 
Note: Do not include symptoms that are clearly attributable to another medical 
condition. 
1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, hopeless) or observation made by 
others (e.g., appears tearful). (Note: In children and adolescents, can be 
irritable mood.) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of 
the day, nearly every day (as indicated by either subjective account or 
observation). 
3. Significant weight loss when not dieting or weight gain (e.g., a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day. (Note: In children, consider failure to make expected weight gain.) 
4. Insomnia or hypersomnia nearly every day. 
5. Psychomotor agitation or retardation nearly every day (observable by others, 
not merely subjective feelings of restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being 
sick). 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide. 
B. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
C. The episode is not attributable to the physiological effects of a substance or to 
another medical condition.  
Note: Criteria A–C represent a major depressive episode (MDE). 
D.  The occurrence of the major depressive episode is not better explained by 
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional 
disorder, or other specified and unspecified schizophrenia spectrum and other 
psychotic disorders. 
E. There has never been a manic episode or a hypomanic episode. 
 
(Andrade et al, 2003). Moreover, MDD has a high comorbidity with anxiety disorders 
(Lamers et al, 2012; Zimmerman et al, 2014). Current and life-time comorbidity rates 
between MDD and anxiety disorders range from 40-80%. Comorbidity of anxiety and 
MDD associates with a specific pattern of vulnerability, such as childhood trauma, 




Course of depression  
The course of MDD is very heterogeneous, ranging from a single-episode, through 
remission followed by relapse (or recovery by recurrence), to a chronic course. Frank 
et al. (1991) have provided some criteria for defining depressive course (Table 1). The 
DSM-5 (American Psychiatric Association, 2013) defines remission as a period of two 
or more months free of symptoms, or with only one or two symptoms less than to a 
mild degree. Chronic depression is defined as a continuous depressed mood (for 
most of the day, for more days than not) lasting for more than two years. 
Table 1. Definitions of depressive course  
Key Terms Definition 
Episode 
Defined as having a certain number of symptoms for a certain period of time, 
fully symptomatic. 
Remission 
Partial remission: the individual is no longer fully symptomatic, but displays 
more than minimal symptoms. Full remission: a brief period (2–8 weeks), 
where the individual is asymptomatic, with no more than the presence of 
minimal symptoms 
Response A partial or full remission due to a treatment intervention 
Recovery 
Defined as a full remission, symptom free for a certain length of time 
(> 8 weeks). It denotes a recovery from an episode 
Relapse 
An early return of symptoms following a positive response, meeting full 
syndrome criteria that occurs during the period of remission 
Recurrence Refers to a new episode, which can only occur during/following a recovery 
Represented from Richards (2011); Original data from Frank et al. (1991). 
Longitudinal clinical studies have suggested that more than 50% of patients 
with an MDE (see Box I) recover within one year (Barkow et al, 2003; Eaton et al, 2008) 
and that the substantial proportion of those who do not recover have a higher chance 
of developing a chronic course (Lamers et al, 2012). Moreover, recurrence is very 
common in patients with MDD even after recovery, with most of them showing 
recurrence within five years after reaching recovery and with recurrence rate 
increasing over time (Keller et al, 2007). Life-time prevalence is almost three times 
higher than the 12-month prevalence, suggesting that at least one-third to one-half of 
MDD individuals experience recurrence in a given year (Kessler and Bromet 2013). 
Recurrence rates over 15 years in clinical samples have been estimated at 85% and in 
the general population at 35% (Hardeveld et al, 2010). Clinical factors such as 
previous episodes of MDD and residual symptoms are more important to predict 




than 10% of MDD patients develop a chronic course (Eaton et al, 2008; Gotlib and 
Hammen 2008). Comorbidity with other disorders and the presence of certain 
symptoms such as severe fatigue, loss of interest, insomnia, suicidal thoughts and 
physical symptoms are predictive of a chronic course of depression (Barkow et al, 
2003; Gilchrist and Gunn 2007).  
Although descriptions of depressive course are provided by Frank et al. (1991) 
and the DSM-5, they are based on observation of behaviors and experiences and not 
necessarily relevant to biological abnormalities. It is still not clear why some MDD 
patients recover, while others experience an enduring unfavorable course. 
Identifying neural markers of the natural course of depression would facilitate early 
detection and intervention in order to minimize cumulative effects, thus preventing 
relapse or an enduring course of depression (Clark et al, 2009). 
Suicidal behavior in depression 
As mentioned above, certain symptoms such as suicidality could predict an 
unfavorable course in depression. The suicide rate is almost eight times higher in 
people with mood disorders than in the general population (Bostwick and Pankratz 
2014). More than half of depressed patients express suicidal ideas and one-third of 
patients with suicidal ideas progress to commit a suicidal act (Kessler et al, 1999; 
Nock et al, 2008). Despite the high correlation between MDD and suicide, some 
depressive patients develop suicidal behaviors, while others do not. Moreover, 
Aleman and Denys (2014) proposed defining suicidality as a distinct disorder, 
because it can occur independently and may not be responsive to effective treatment 
of depressive symptoms. However, it remains unclear whether suicidality can be 
viewed as a distinct disorder in terms of neurobiological dysfunction as well. 
Therefore, investigating the neural substrate that is specific for suicidality in 
depression may help to further differentiate the distinct mechanism of suicidality 
from depression.  
Neural models in affective psychopathology 
In recent decades, studies of emotional and cognitive processing in depression have 
provided a body of evidence regarding the behavioral and neural bases of emotional 
and cognitive processing disturbances. The most consistent finding is the presence of 
a cognitive emotional bias, represented by enhanced attention and memory for 
negative emotional information and diminished attention/memory for positive 
emotional information (Beck 2008; Disner et al, 2011; Gotlib and Joormann 2010; 
Leppänen 2006). Biases in attention and memory may have some consequences such 
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BOX II. Neurobiological Models of Psychiatric Disorders  
A cognitive-neurobiological model proposed by Disner (2011) in an attempt to 
integrate the cognitive model of depression (Beck, 1967; Beck et al, 2002) with more 
recent structural and functional neuroimaging findings, suggests that a specific neural 
substrate underlies biases in perception, attention and memory in depression. In this 
model, two compartments of processing are involved: a bottom-up (limbic-cortical) 
pathway that starts from hyper-responsivity in the limbic system (especially in amygdala) 
and continues through the subgenual part of the anterior cingulate cortex (ACC), caudate, 
putamen, nucleus accumbens and hippocampus to the prefrontal (cortical) regions (PFC). 
A top-down (cortical-limbic) pathway begins with reduced activation of prefrontal cognitive 
control areas and proceeds to inhibit the top-down control through thalamus and ACC to 
subcortical regions. The bottom-up pathway is unrestrained by top-down cognitive 
control, which may enhance the cognitive biases and prolong the depressive course.  
This limbic-cortical inhibition model is a refinement of at least two other previous 
neuroanatomical models on depressive phenomenology proposed by Mayberg (1997) 
and Phillips et al. (2003). In Mayberg’s model, the dorsal neocortical system (dorsolateral 
PFC, hippocampus) mediating the sensory-cognitive aspect of MDD and ventral 
subcortical system (amygdala, insula, ventral striatum, thalamus and subgenual ACC) 
mediating vegetative and somatic aspect of MDD are proposed. Additionally, a regulatory 
hub (rostral cingulate) is highlighted to connect these two systems. 
The model developed by Phillips et al. (2003) aimed to illustrate disturbances in 
emotional processing in a variety of psychiatry disorders. This model proposes that 
enhanced bottom-up regulation from a ventral system (amygdala, insula, ventrolateral 
PFC, ventral striatum) and weak top-down regulation from a dorsal system (dorsolateral 
PFC, dorsomedial PFC, ACC and hippocampus) are prominent features in MDD, which 
leads to abnormal appraisal of negative incoming information underlying depressed mood 
and anhedonia, which further reinforces the cognitive bias and perpetuate depression.  
Moreover, this model suggests that, in schizophrenia, the pattern of structural and 
functional neural abnormalities in the ventral system may cause deficient emotion 
identification, and subsequent interpretation of all information as threatening, thereby 
result in specific negative and positive symptoms including flat emotion, anhedonia, 
persecutory delusions, and impaired social function. These maladaptive processes and 
as inflexible appraisals, which hamper the selection of deliberate reappraisals to 
regulate emotions (Siemer and Reisenzein 2007). In this section, I will introduce some 
important neuroanatomical models proposed to explain the affective disturbances 




Continued BOX II. 
negative symptoms might be maintained by abnormalities within the dorsal system, 
involved in reasoning, contextual processing, and effortful regulation of affective states. In 
contrast, the pattern of abnormalities in the ventral system in bipolar disorder has been 
posited to be associated with oversensitivity to emotional information and a disturbance 
to effectively regulate emotion, thus further resulting in certain manic and depressive 
symptoms, such as mood fluctuation, emotional burden, and distractibility. 
Unlike the cyclical limbic-cortical inhibition models mentioned above, a recent 
neural model of negative bias in depression proposed a unidirectional pattern of neural 
substrates: signals from the limbic areas (amygdala and dorsal ACC) fail to project to the 
upward cortical-striatal-pallidal-thalamic circuit, leading to under-responsiveness to 
negative stimuli in the dorsal areas (dorsal striatum and dorsolateral PFC) (Hamilton,J.P. 
2012). Furthermore, a temporal profile of affective processing in depression is suggested 
by this ascending trajectory, which implies that emotional significance is firstly registered 
as a sensory signal in the limbic system, and then proceeds through a higher-level 

















Aim and outline of this thesis 
Current diagnoses in clinical psychiatry are based on clusters of symptoms and 
clinical course but virtually lack relevant biological measurements (Phillips 2012). 
Therefore, the application of basic and clinical neuroscience research for identifying 
pathophysiological biomarkers has been highlighted in the development of the 
recent released DSM-5 in order to facilitate early detection and effective diagnosis of 
psychiatric disorders (Charney et al, 2002). As one of the most important 
neuroimaging measures, fMRI examines a proxy measure of neural activity (i.e. 
changes in blood oxygen level-dependent or BOLD signal) under certain task 
requirements targeting different cognitive processes. It has been widely used to 
investigate the neural basis of cognitive and affective abnormalities in clinical 
populations, which might constitute potentially useful neural markers. However, 
there are still some remaining questions to be addressed. 
Memory biases have been associated with depression and have been shown to 
be predictive of depressive course (Johnson et al, 2007). However, the current models 
on depression (See box II) are mostly focused on the neural correlates of processing 
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negative stimuli, but do not consider a bias for positive stimuli. Importantly, studies 
have found that the cognitive performance during processing of positive information 
was improved after using anti-depressants (Geschwind et al, 2011; Harmer et al, 2009; 
Norbury et al, 2009) and processing of positive information was predictive of 
treatment response (Geschwind et al., 2011), which implies an approach to identify 
neural markers of depressive course during processing of both positive and negative 
stimuli. Moreover, neuroimaging studies using fMRI have consistently indicated the 
importance of neural mechanisms for predicting remission following treatment, 
including morphology and functioning of the frontal regions (Heller et al, 2013; 
Langenecker et al, 2007; Ritchey et al, 2011), and limbic regions (Frodl et al, 2004; Fu et 
al, 2013; Langenecker et al, 2007). Although treatment studies could establish the 
effectiveness of a medication at various stages of depression, it is important to 
understand the natural course of depression because it is more akin to the every-day 
experience of patients and clinicians, and thus of ecological validity. In addition, a 
naturalistic prospective investigation could elucidate the neurocognitive mechanisms 
predicting long-term episodic stages of depression (Frodl et al, 2008) and facilitate 
early detection and intervention to minimize cumulative effects (Clark et al, 2009). 
Therefore, in chapter 2, using a cross-sectional prospective design, we aimed to 
investigate the relationship between regional brain activation during both positive 
and negative word encoding and recognition related to the naturalistic course of 
depression. 
As a key factor for the development and maintenance of MDD (Disner et al, 
2011; Leppänen 2006), a mood-congruent memory bias has been shown in both 
depressed and remitted MDD patients. Despite that mood-congruent and mood-
incongruent information have been shown to activate distinct areas during encoding 
and recognition (Fitzgerald et al, 2011; Van Wingen et al, 2010), it is unclear whether 
the limbic-cortical dysregulations proposed in these models represent stable 
abnormalities in depression, or are subject to changes in clinical state. Moreover, 
although Mayberg’s model describes the unique pattern of changes in brain 
activation with different treatments, no study has investigated how the brain changes 
within a naturalistic course of depression. Therefore in chapter 3, we reported a 
longitudinal fMRI study of emotional memory processing to clarify whether 
abnormal activation progresses further as a function of depressive load or may serve 
as state-dependent biomarkers of MDD course. 
Structural and functional abnormalities during affective processing are 
associated with specific symptoms in psychiatric disorders in previous models (See 




depression so far. Suicidal behavior is a common symptom in psychiatric disorders, 
especially in mood disorders such as MDD (Bernal et al, 2007; Haukka et al, 2008; 
Hawton and van Heeringen 2009; Nock et al, 2009). Similar to MDD patients in 
general, suicidal patients show abnormalities in emotion processing and cognitive 
control (Jollant et al, 2011). However, not all MDD patients show signs of suicidal 
ideation and attempts, and it is difficult to identify whether subjects with suicidal 
ideation with a diagnosis of MDD go on to make suicide plans or attempts. 
Elucidating the neurobiological factors related to suicidality (ideation or attempts) 
would not only help to identify biomarkers for development of suicidal behavior, but 
would provide valuable information for clinicians that guide assessment and 
treatment of depressive individuals with suicidal ideation. To this end, in chapter 4, 
we examined distinct mechanisms of emotion processing (emotional faces task) and 
executive functioning (Tower of London) at different stages of suicidality in 
depressed patients in order to identify the distinct mechanisms of suicidality. 
As a core vulnerability factor in many psychiatric disorders, emotion 
dysregulation has been reported in both patients with bipolar disorder and 
schizophrenia, although strategies and underlying mechanisms may differ. 
Hypofrontality has consistently been found in SZ patients (Morris et al, 2012; van 
der Meer et al, 2014), suggestive of a failure to engage frontal regions during 
emotion down-regulation. In contrast, bipolar disorder has been associated with 
hyperfrontality (Morris et al, 2012) as well as hypofrontality (Townsend et al, 2013) 
during the down-regulation of negative emotions. Although these appear to 
indicate distinct patterns of brain activation during emotional control, it is unclear 
whether inefficient regulation in bipolar patients are due to the disability to 
perpetuate the initial frontal engagement during the whole process of effortful 
regulation, or due to a failure to engage frontal regulatory areas per se. Similarly, 
whether frontal control deficits are an early, late or constant characteristic in 
schizophrenia patients is unknown. The temporal feature from Hamilton’s model 
(See Box II) may be disrupted in depressed patients, leading to and a failure of 
reappraisal of negative information and a sustained negative bias. Hence, in chapter 
5, we investigated the temporal profile of brain activation underlying cognitive 
emotion regulation (reappraisal) in patients with bipolar disorder and 
schizophrenia, which would be essential to understand how emotion dysregulation 
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